Keith D. Aaronson

New England Journal of Medicine · 2005–2019

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Whom Keith D. Aaronson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Eric J. Topol

Who trusts Keith D. Aaronson overall

  1. C. Yancy
  2. M. Gheorghiade

Papers from Keith D. Aaronson's perspective

Ordered by how strongly the researchers Keith D. Aaronson trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Long-term use of a left ventricular assist device for end-stage heart failure. (New England Journal of Medicine)
  2. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. (New England Journal of Medicine)
  3. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure (Circulation)
  4. Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study (Circulation)
  5. Failing the public health--rofecoxib, Merck, and the FDA. (New England Journal of Medicine)
  6. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. (Journal of the American Medical Association (JAMA))
  7. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review (British medical journal)
  8. Blood transfusion in elderly patients with acute myocardial infarction. (New England Journal of Medicine)
  9. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? (Critical Care Medicine)
  10. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. (New England Journal of Medicine)

Their papers